• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    1/27/25 4:30:09 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LCTX alert in real time by email
    8-K
    false000087634300008763432025-01-272025-01-27

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 27, 2025

     

     

    Lineage Cell Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    California

    001-12830

    94-3127919

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2173 Salk Avenue, Suite 200

     

    Carlsbad, California

     

    92008

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (442) 287-8990

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common shares

     

    LCTX

     

    NYSE American LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On January 27, 2025, Lineage Cell Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”), held a special meeting of shareholders. The matters voted upon at the meeting are described in detail in our definitive proxy statement for the meeting, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 9, 2024. Below is a brief description of each such matter and the final voting results, including the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.

    1.
    Shareholders approved, for purposes of complying with NYSE American LLC listing standards and requirements, the issuance of our common shares and common warrants pursuant to the terms of the securities purchase agreement, dated November 19, 2024, between us and Broadwood Partners, L.P., and our common shares issuable upon exercise of such common warrants.

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    114,132,309

    6,732,082

    362,083

    0

    2.
    Shareholders approved the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of proposal 1 if there were not sufficient votes to approve such proposal at the time of the meeting or any adjournment or postponement thereof.

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    112,392,014

    8,458,712

    375,748

    0

    Item 7.01 Regulation FD Disclosure.

    On January 27, 2025, we issued a press release announcing the closing of the offering described in Item 8.01 of this report, a copy of which is furnished as Exhibit 99.1 hereto.

    The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of our filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

    Item 8.01 Other Events.

    Following receipt of stockholder approval of proposal 1 described in Item 5.07 of this report, we closed the second tranche of the registered direct offering announced on November 20, 2024. In connection with such closing, we issued 7,894,737 common shares and an accompanying warrant to purchase an aggregate of up to 7,894,737 common shares, at a combined purchase price of $0.76 per common share and accompanying warrant, to Broadwood Partners, L.P., an affiliate of Neal Bradsher, a member of our board of directors. Such warrant will be exercisable for one common share at an exercise price of $0.91 per common share commencing on May 21, 2025 and will expire on the earlier of (a) May 21, 2028, and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen® (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, the 90th day following May 21, 2025. The foregoing description of the warrant does not purport to be complete and is qualified in its entirety by the full text thereof, a copy of which is attached as an exhibit 4.1 to this report and incorporated by reference herein.

    We received $6 million in gross proceeds at the closing, before deducting placement agent’s fees and other offering expenses payable by us. We received $24 million in gross proceeds at the first closing of the offering in November 2024 and may receive up to an additional $36 million of gross proceeds upon the exercise in full on a cash basis of the warrants issued in the offering. No assurance can be given that any of the warrants issued in the offering will be exercised on a cash basis, or at all. We currently plan to use the net proceeds from the offering for working capital and general corporate purposes, including research and development expenses and capital expenditures.

    We also issued warrants to H.C. Wainwright & Co., who acted as the exclusive placement agent for the offering, or its designees to purchase an aggregate of up to 394,736 common shares. Such warrants have substantially the same terms as the warrant described above, except they have an exercise price of $0.95 per common share.

    The securities described above were offered and sold by Lineage in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (File No. 333-277758) filed with the SEC on March 7, 2024, and which was declared effective by the SEC on May 14, 2024. The offering of the securities in the registered direct offering was made only by means of a base prospectus and a prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov.


    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    4.1

    Warrant issued to Broadwood Partners, L.P. on January 27, 2025

    99.1

    Press release issued on January 27, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Lineage Cell Therapeutics, Inc.

     

     

     

     

    Date:

    January 27, 2025

    By:

    /s/ George A. Samuel III

     

     

    Name:

    Title:

    George A. Samuel III
    General Counsel and Corporate Secretary

     


    Get the next $LCTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LCTX

    DatePrice TargetRatingAnalyst
    8/20/2024$4.00Buy
    Craig Hallum
    11/2/2022$5.00Outperform
    Robert W. Baird
    6/14/2022$4.00Buy
    B. Riley Securities
    8/19/2021$8.00Outperform
    Noble Capital Markets
    More analyst ratings

    $LCTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

      Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical   Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp

      5/21/24 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lineage Announces Appointment of General Counsel

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp

      9/1/21 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Financials

    Live finance-specific insights

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di

      3/5/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking

      11/14/24 4:01:00 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

      Fully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advoc

      4/22/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

      Lineage Participating in Panel Discussion of Novel Retina Drug Delivery Approaches at Eyecelerator@ Park City 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of the "I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina" panel at Eyecelerator@ Park City 2025. The panel will take place on Friday, May 2, 2025 from 12:30pm to 1:30pm M

      4/21/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    SEC Filings

    See more
    • Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      5/1/25 9:09:09 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Lineage Cell Therapeutics Inc.

      DEFA14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:10:04 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Lineage Cell Therapeutics Inc.

      DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:05:15 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      1/28/25 7:49:41 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Howe Jill Ann bought $8,850 worth of shares (15,000 units at $0.59), increasing direct ownership by 143% to 25,500 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:58:31 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Samuel George A. Iii bought $9,000 worth of shares (15,000 units at $0.60), increasing direct ownership by 209% to 22,184 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:55:46 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $LCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Culley Brian M

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:54 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Howe Jill Ann

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:36 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by General Counsel and Secretary Samuel George A. Iii

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:11 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      11/21/24 8:05:56 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      2/8/24 6:57:07 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      3/25/22 5:23:02 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Craig Hallum initiated coverage on Lineage Cell Therapeutics with a new price target

      Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      8/20/24 8:32:59 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Lineage Cell Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00

      11/2/22 6:28:33 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on Lineage Cell Therapeutics with a new price target

      B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      6/14/22 7:59:45 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care